Viatris (VTRS) said Wednesday its phase 3 trial in Japan evaluating EFFEXOR for generalized anxiety disorder met its primary objective, showing superiority over placebo in reducing anxiety symptoms at eight weeks.
The trial, which assessed 804 patients, met primary and all secondary efficacy endpoints, Viatris said. EFFEXOR was generally well tolerated, with low discontinuation rates and no severe treatment-emergent adverse events, it added.
Viatris shares were up 0.7% in recent premarket activity.
Price: 11.40, Change: +0.08, Percent Change: +0.71
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。